Bdparib 200 mg (Rucaparib)
| Active Ingredient | Rucaparib |
|---|---|
| Indication: | Treatment of Prostate and Ovarian Cancers |
| Manufacturer: | BDR Pharmaceuticals |
| Packaging | 60 Tablets in bottle |
| Strength | 200mg |
Bdparib 200mg contains Rucaparib, a PARP inhibitor (poly ADP-ribose polymerase inhibitor) used in the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, particularly in patients with BRCA gene mutations. It is most often prescribed in advanced or relapsed cases, including as maintenance therapy after successful platinum-based chemotherapy.
Rucaparib works by interfering with cancer cells’ ability to repair their DNA, leading to cell death—particularly in tumors with BRCA mutations that are already DNA-repair deficient. Bdparib 200 mg tablets are taken orally, usually twice daily, and are monitored closely by an oncologist for efficacy and side effects.








There are no reviews yet.